Many potential catalysts seen for DelMar Pharma by SeeThruEquity analysts

12 May 2015

Canadian biotech firm DelMar Pharmaceuticals (OTCQB: DMPI), focused on proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments, is the subject of a positive update note from US equity research firm SeeThruEquity.

"We see many potential catalysts ahead for DMPI in 2015, and are encouraged by several announcements by the company during April, including development program updates from the Annual Meeting of the American Association for Cancer Research (AACR), which took place in Philadelphia, PA, from April 18 to April 22, 2015. We are reaffirming our 12 month price target of $4.53 per share," commented Ajay Tandon, chief executive of SeeThruEquity.

Early research on VAL-083 encouraging

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK